Seven investors provide $25m for Viamet Pharmaceuticals.
Viamet Pharmaceuticals, a US-based drugs company formerly known as Hephistics, has raised $25m from seven investors, according to a regulatory filing.
Lilly Ventures and Novartis Option fund, the two corporate venturing units of Eli Lilly and Novartis respectively, have board members at Viamet (Edward Torres and Lauren Silverman, respectively).
In February last year, Novartis licensed Viamet’s proprietary Metallophile Technology for an upfront fee and potential milestones totaling more than $200m as well as product royalties.
Silverman, managing director of…
